Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Broad Institute of Mit and Harvard
Headquarters: Cambridge, MA, United States of America
Website: http://www.broadinstitute.org...
Year Founded: 2003
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Mar 12, 2025
Discovery & Translation
Science Spotlight: Killing the mesenchymal precursors that drive cancer progression
BioCentury’s roundup of translational innovations also includes blood detection of pregnancy complications, BBB-crossing antibodies, and more
BioCentury | Feb 15, 2025
Discovery & Translation
Science Spotlight: Using HIV to help allogeneic CAR T cells evade immune attack
BioCentury’s roundup of translational innovations also includes a human hypothalamus atlas from Novo and collaborators, and four papers with links to newcos
BioCentury | Feb 7, 2025
Discovery & Translation
Science Spotlight: New protein degradation mechanism
BioCentury’s roundup of translational innovations also includes new insight into repeat expansion in Huntington’s and 10 new products
BioCentury | Jan 27, 2025
Discovery & Translation
Science Spotlight: Improving safety of live-attenuated vaccines
BioCentury’s roundup of translational innovations also includes base editing for prion disease, a Flagship collab, and six papers with links to newcos
BioCentury | Dec 19, 2024
Discovery & Translation
Science Spotlight: Platelets as targeted protein degraders
BioCentury’s roundup of translational innovations also includes ribonucleoproteins delivery and fine-tuning TCR specificity
BioCentury | Dec 12, 2024
Deals
Nvelop, Chroma merger creates opportunity for targeted epigenome editors
Nvelop CEO Jeff Walsh will lead nChroma, which has $75M in new funding and a lead for HBV
BioCentury | Nov 27, 2024
Discovery & Translation
Science Spotlight: Reducing immune rejection of stem cell-derived therapies
BioCentury’s roundup of translational innovation also includes a new target for arrhythmia and four papers with links to newcos
BioCentury | Nov 12, 2024
Discovery & Translation
Learning human biology: a Q&A with Genentech’s Nikhil Wagle
The head of Genentech’s two-year-old Translational Medicine unit on patient samples as a portal to discovery, precision and “custody of mechanism”
BioCentury | Oct 31, 2024
Discovery & Translation
Science Spotlight: Macrophage-fibroblast cross-talk in heart failure
BioCentury’s roundup of translational innovations also includes synthetic gene regulators, three longevity genes and more
BioCentury | Oct 23, 2024
Discovery & Translation
Science Spotlight: Novo’s glucose-sensing insulin, two bacterial immunotherapies, and more
BioCentury’s roundup of translational innovations
Items per page:
1 - 10 of 550